Bausch Health has licensed Eyenovia to develop and commercialize an investigational formulation of atropine delivered by Optejet dispenser, according to a press release.
Under the terms of the agreement, Bausch will assume oversight and costs of the phase 3 CHAPERONE clinical trial, which is underway to investigate efficacy of a microdose formulation of atropine to slow myopia progression in pediatric patients, and develop and commercialize the formulation, which is delivered by Eyenovia’s proprietary dispenser technology, in the U.S. and Canada.
A $10 million upfront payment to Eyenovia
Uncategorized